COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

COVID-19 Briefings

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.

FDA Issues Four New Warning Letters for Adulterated and Misbranded COVID-19 Tests

FDA maze of regulations
Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on whatsapp
Share on email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

FDA continues crackdown on unauthorized COVID-19 tests.

On Aug. 12, 2020, the US Food and Drug Administration (FDA) posted four warning letters that were issued during the last two weeks of July. These four warning letters addressed adulterated and misbranded COVID-19 tests that had not received emergency use authorization (EUA) and were not permitted to be marketed or sold in the United States. 

FDA warning letters were issued to:

  • Fair Price Labs, Inc. This warning letter addressed claims made about Fair Price Labs’ DROPTM SARS-CoV-2 virus ELISA IgG and IgM Self-Collection Test Kit. These claims included instructions that the test could be taken at home via a finger stick and that the specimen could be sent to their lab.
  • CoreMedica Laboratories, Inc. This warning letter addressed CoreMedica Laboratories’ COVID-19 (SARS-CoV-2) ANTIBODY SCREENING KIT Specimen Self-Collection and Transport Kit, which claims to provide at-home antibody testing that involved a finger stick and mailing the sample to the company’s lab.
  • Holistic Health International, LLC. This warning letter addressed Holistic Health International’s SARS-COV-2 STOOL TEST (SCV), which claims to be a stool-based SARS-CoV-2 diagnostic test that could be collected at home.
  • AkivaMed Inc. This warning letter addressed AkivaMed’s COVID-19 Antibody Rapid Test Kit, which claims to be an at-home COVID-19 antibody test and does not describe how this test is collected.

The common factor in each of these adulterated and misbranded COVID-19 tests is that they are marketed for at-home use. These new warning letters indicate increased attention by the FDA to at-home tests. While the FDA recently released an EUA template for at-home COVID-19 testing, no EUAs have yet been issued for this kind of test.

Related Resources:

FDA Warning Letter: Fair Price Labs, Inc.

FDA Warning Letter: CoreMedica Laboratories, Inc.

FDA Warning Letter: Holistic Health International, LLC.

FDA Warning Letter: AkivaMed Inc.

FDA Warning Letters History


Helping Your Lab Stay Afloat During Challenging Times

Dear Colleague,

Robert L. MichelIn these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.

We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.

Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at


Robert L. Michel
President, Founder
The Dark Intelligence Group